Searching…
Abstract Background: Primary analysis of the phase III trial BG01-1323L demonstrated that utidelone plus capecitabine significantly improved progression-free survival (PFS) and overall response rate (ORR) versus capec...
Jun 1, 2018 · Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.
Apr 8, 2023 · 一项国内多中心随机对照研究（BG01-1312L 研究）结果显示，优替德隆加卡培他滨相比单药卡培他滨不仅可以显著延长无进展生存期，总生存也得以改善。 加之优替德隆可及性的提高，优替德隆加卡培他滨方案的推荐顺序得以提高，证据等级从 2A 改为 1A。
Mar 9, 2023 · 优替德隆作用机制与紫杉醇相似，但与紫杉醇的结合位点不完全相同，克服了紫杉类药物的耐药问题，不易产生耐药，为紫杉类治疗失败的晚期乳腺癌患者提供了有效的治疗新选择，其疗效BG01-1312L研究中已充分证明。
Jun 17, 2024 · STUDY-304 和 BG01-1312L 研究分别证明了艾立布林、优替德隆用于二线及二线以上治疗整体晚期乳腺癌有所获益，但对于晚期三阴性乳腺癌亚组患者，则未 ...
Utidelone Plus Capecitabine vs Capecitabine for Anthracycline- and Taxane-Refractory MBC: A Multicenter, Randomized Phase III Trial (BG01-1312L) Sign in to explore collection of abstracts, journal articles, posters, v...
Jun 30, 2016 · 该研究确立了 Palbociclib 在 ER＋HER2－晚期乳腺癌的一线和二线治疗中的地位。 ESR1 基因是否能常规检测作为药物选择的依据，还需要更多的研究来验证。
Mar 12, 2021 · BG01-1312L研究由中国医学科学院肿瘤医院徐兵河教授牵头，研究结果分别两次入选ASCO（美国临床肿瘤学年会）大会口头汇报，并发表于国年际知名肿瘤学期刊Lancet Oncology和Annals of Oncology。
Oct 9, 2020 · Our study is a single-center analysis and investigative study that aims to assess the efficacy of utidelone combined with capecitabine in Chinese patients with metastatic breast cancer that had been pret...
Feb 15, 2020 · Objective In BG01-1323L trial, Utidelone, a novel genetically engineered epothilone analogue, plus capecitabine showed improved progression-free survival and overall survival in heavily pretreated metas...
